Comparative studies on susceptibility and minimum inhibitory concentration of potentox, a fixed dose combination of cefepime amikacin in Proteus vulgaris, Escherichia coli and Bacillus subtilis

Journal of Medical Sciences

Volumn 9, Issue 5, 2009, Pages 245-248

  Shrivastava, Sanjay Mohan ^a   Chaudhary, M ^a  

^a Venus Medicine Research Centre   (India)

Author keywords

Amikacin; AST; Cefepime; MIC; Potentox

Indexed keywords

AMIKACIN; AMIKACIN PLUS CEFEPIME; ANTIINFECTIVE AGENT; CEFEPIME; POTENTOX; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; ESCHERICHIA COLI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEUS VULGARIS;

EID: 73849111975     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2009.245.248     Document Type: Article

References (18)

1. Angelescu, M. and A. Apostol, 2001. Cefepime (maxipime), large spectrum 4th generation cephalosporin, resistant to β-lactamases. Chirurgia, 96: 547-552.
2. Barradell, L.B. and H.M. Bryson, 1994. Cefepime: A review of its antibacterial activity pharmacokinetic properties and therapeutic use. Drugs, 47: 471-505.
3. Bhat, S.V., A.Y. Peleg, T.P. Lodise, K.A. Shutt, B. Capitano, B.A. Potosky and D.L. Paterson, 2007. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob. Agents Chemother., 51: 4390-4395.
4. Brun-Buisson, C., P. Legrand, A. Philippon, F. Montravers, M. Ansquer and J. Duval, 1987. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet, 2: 302-306.
5. Caron, F.L., A. Gutmann, B. Bure, J.M. Pangon, A. Vallois, Pechinot and C. Carbon, 1990. Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 β-lactamase. Antimicrob. Agents Chemother., 34: 2070-2074.
6. Chaudhary, M., S.M. Shrivastava, L. Varughese and R. Sehgal, 2008. Efficacy and safety evaluation of Fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients. Curr. Clin. Pharmacol., 3: 118-122.
7. Clarke, A.M., S.J.V. Zemcov and J.M. Wright, 1985. HR 810 and BMY-28142 two new cephalosporins with broad spectrum activity: An in vitro comparison with other β-lactam antibiotics. J. Antimicrob. Chemother., 15: 305-310.
8. French, G.L., 2005. Clinical impact and relevance of antibiotic resistance. Adv. Drug Del. Rev., 57: 1514-1527.
9. Hughes, W.T., D. Armstrong, G.P. Bodey, A.E. Brown and J.E. Edwards et al., 1997. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin. Infect. Dis., 25: 551-573.
10. Jacoby, G.A. and A.A. Medeiros, 1991. More extended spectrum β-lactamases. Antimicrob. Agents Chemother., 35: 1697-1704.
11. Jett, B.D., D.J. Ritchie, R. Reichley, T.C. Bailey and D.F. Sahm, 1995. In vitro activities of various β-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. Resistant to oxyimino cephalosporins. Antimicrob. Agents Chemother., 39: 1187-1190.
12. Kessler, R.E., M. Bies, R.E. Buck, D.R. Chisholm and T. Pursiano et al., 1985. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum β-lactam antibiotics. Antimicrob. Agents Chemother., 27: 207-216.
13. Phelps, D.J., D.D. Carlton, C.A. Farrell and R.E. Kessler, 1986. Affinity of cephalosporins for β-lactamases as a factor in antibacterial efficacy. Antimicrob. Agents Chemother., 29: 845-848.
14. Shrivastava, S.M., S. Saurabh, D. Rai and M. Chaudhary, 2008. Comparative evaluation of microbial efficacy of potentox, a fixed dose combination of cefepime amikacin with cefepime and amikacin alone. J. Nat. Conserv., 20: 121-126.
15. Song W., E.S. Moland, N.D. Hanson, J.S. Lewis, J.H. Jorgensen and K.S. Thomson, 2005. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J. Clin. Microbiol., 43: 4891-4894.
16. Thauvin-Eliopoulos, C., M.F. Tripodi, R.C. Jr. Moellering and G. M. Eliopoulos, 1997. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra abdominal abscesses due to an extended-spectrum β-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother., 41: 1053-1057.
17. Tsuji, A., A. Maniatis, M.A. Bertram and L.S. Young, 1985. In vitro activity of BMY 28142 in comprision with those of other β-lactam antimicrobial agents. Antimicrob. Agents Chemother., 27: 515-519.
18. Wynd, M.A. and J.A. Paladino, 1996. Cefepime: A fourth-generation parenteral cephalosporin. Ann. Pharmacother., 30: 1414-1424.